News and Events

News

Algok Bio and Institute of Cancer Research (ICR) Launch Phase 1b Trial of Idetrexed with PARP Inhibitor Lynparza for Ovarian Cancer

News

Algok Bio Enters into Exclusive Worldwide License Agreement with BTG to Develop and Commercialize Idetrexed, a Clinical-Stage Folate Receptor-Targeted Oncology Drug